Lexicon Pharmaceuticals to participate in Citi Biopharma Back to School Conference.

Lexicon Pharmaceuticals management will participate in two fireside chats at the Citi Biopharma Back to School Conference and the H.C. Wainwright Global Investment Conference. The events will be live-streamed and available on Lexicon's website. Lexicon is a biopharmaceutical company with a mission to transform patients' lives through pioneering medicines. The company's Genome5000 program identified protein targets with therapeutic potential in various diseases.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) has announced its participation in two upcoming investor conferences in September 2025. The company will present at Citi's Biopharma Back to School Conference on September 3 at 1:45 p.m. ET and at the H.C. Wainwright 27th Annual Global Investment Conference on September 8 at 3:00 p.m. ET. Both presentations will be available via live webcast and replay through Lexicon's investor relations website at investors.lexpharma.com.

Lexicon Pharmaceuticals is a biopharmaceutical company with a mission to transform patients' lives through pioneering medicines. Through its Genome5000™ program, the company's unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. By precisely targeting these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. The company has advanced multiple medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, obesity, cardiology, diabetes, and other indications.

Lexicon Pharmaceuticals' strategic retrenchment, which involved cutting commercial operations and 60% of its workforce, has allowed the company to focus exclusively on advancing its pipeline. The company's R&D focus targets high-impact therapies with first-in-class potential in underserved markets. For instance, Pilavapadin, a non-opioid oral candidate for diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia, is currently in Phase 2 trials and is expected to enter Phase 3 trials in 2025. With patents extending to 2040, Pilavapadin could address a $3 billion market if approved.

Lexicon's success hinges on the outcomes of Phase 3 trials and the expansion of partnerships. The company's licensing deal with Novo Nordisk for LX9851, a non-incretin obesity candidate, generated $45 million upfront and potential milestone payments of up to $1 billion. Such arrangements provide non-dilutive capital, allowing Lexicon to retain control over its pipeline while mitigating the financial burden of commercialization.

The upcoming investor conferences provide an opportunity for investors and financial professionals to learn more about Lexicon Pharmaceuticals' strategic direction, pipeline, and financial health. The live events and replays can be accessed via the Events page of the Company’s website at https://investors.lexpharma.com/.

For additional information, please visit www.lexpharma.com.

For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com

References:
[1] https://www.globenewswire.com/news-release/2025/08/27/3140013/0/en/Lexicon-Pharmaceuticals-to-Participate-at-Two-Upcoming-Investor-Conferences.html
[2] https://finance.yahoo.com/news/lexicon-pharmaceuticals-participate-two-upcoming-123000577.html
[3] https://www.marketscreener.com/news/lexicon-pharmaceuticals-to-participate-at-two-upcoming-investor-conferences-ce7c50dedc8dfe26
[4] https://www.stocktitan.net/news/LXRX/lexicon-pharmaceuticals-to-participate-at-two-upcoming-investor-vjrlbdpaf0hm.html
[5] https://www.ainvest.com/news/lexicon-pharmaceuticals-strategic-retrenchment-focus-pathway-long-term-creation-2508/